Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN301 in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20222409Phase 2Terminated
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of STRO-001 in B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), mantle cell lymphoma (MCL), sponsored by Sutro Biopharma, Inc.. Started Sep 2022; status: terminated.
02
Drugs
STRO-001
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20222409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222409.